Foundayo vs Rybelsus
Editorial comparison of Foundayo (orforglipron) and Rybelsus (semaglutide (oral)). Same drug class context, trial-anchored data, no marketing claims.
Jump to section
Side-by-side
| Dimension | Foundayo | Rybelsus |
|---|---|---|
| Generic name | orforglipron | semaglutide (oral) |
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA approved | 2026 | 2019 |
| Mechanism | Same target as injectable GLP-1s — the GLP-1 receptor — but a non-peptide small-molecule structure. | GLP-1 receptor agonist, identical mechanism to injectable semaglutide. |
| Dosing | Once-daily oral tablet, titrated upward over several weeks to manage GI side effects. | Once daily on an empty stomach with ≤4 oz water, 30 minutes before food/drink/other meds. Titrated 3mg → 7mg → 14mg. |
| Cost | LillyDirect self-pay: $149/month for 0.8 mg and 2.5 mg, $199 for 5.5 mg, and $299 for 9 mg, 14.5 mg, and 17.2 mg. | List ~$900-1,000/month. Diabetes coverage generally better than weight-loss coverage. NovoCare self-pay options available for eligible patients. |
| Pivotal trial result | 11.2% mean body-weight reduction at 72 weeks on the top dose vs 2.1% placebo (ATTAIN-1 Phase 3) | — |
HealthRX
from $99/mo
- Online visit with a US-licensed clinician
- Prescription only if clinically appropriate
You only pay if you and a clinician decide to start treatment.
- US-licensed clinician
- HIPAA compliant
- Sponsored — we earn commission
Efficacy in the trials
11.2% mean body-weight reduction at 72 weeks on the top dose vs 2.1% placebo (ATTAIN-1 Phase 3)
ATTAIN-1 / ACHIEVE program · vs placebo; oral dosing without injection · n=3,000
No head-to-head pivotal-trial figure on file. See the full Rybelsus review.
Trial averages describe study populations, not individuals. Response varies with the dose tolerated, adherence, and personal physiology; the two drugs were not necessarily tested head-to-head in the same trial.
The details
Dosing & cadence
Cost & access
Side effects
Which should you choose?
Neither has a decisive headline-efficacy edge in the catalog data, so the deciding factors are usually tolerability, dosing, and cost. On cost and access, compare each drug's manufacturer direct-pay and insurance path — that often matters more month-to-month than the efficacy gap. Both carry class safety considerations (see each drug's boxed-warning and contraindications); a personal or family history of medullary thyroid carcinoma or MEN2 rules out the GLP-1 class. Bring this comparison to a prescriber, who will match the drug to your history and titrate the dose.
This is editorial framing, not a prescription. The right choice depends on your medical history, insurance, and a clinician's evaluation.
Full Foundayo review →
Once-daily oral non-peptide GLP-1 for chronic weight management, FDA-approved April 1, 2026. LillyDirect self-pay from $149/month. No injection, no compounded versions.
Full Rybelsus review →
Oral semaglutide tablet for type 2 diabetes. Same molecule as Ozempic/Wegovy in pill form, with strict fasting-and-water dosing rules.
Deciding at the molecule level? Semaglutide vs Tirzepatide compares the two drug families behind every major GLP-1 brand.
Frequently asked
Is Foundayo or Rybelsus more effective?+
In their pivotal trials, Foundayo reported 11.2% mean body-weight reduction at 72 weeks on the top dose vs 2.1% placebo (ATTAIN-1 Phase 3), while Rybelsus reported no headline result on file. Head-to-head results vary by patient profile, dose tolerated, and adherence — these trial numbers describe averages, not what every individual experiences.
How do Foundayo and Rybelsus compare on cost?+
Foundayo: LillyDirect self-pay: $149/month for 0.8 mg and 2.5 mg, $199 for 5.5 mg, and $299 for 9 mg, 14.5 mg, and 17.2 mg. The 2.5 mg and 5.5 mg prices are introductory through December 31, 2026; the 14.5 mg and 17.2 mg price requires a refill within 45 days. With commercial insurance that covers it, the Foundayo savings card can lower the cost to as little as $25/month (savings capped at $100/month, through December 31, 2026). Medicare GLP-1 Bridge: $50/month from July 1, 2026 to December 31, 2027. Rybelsus: List ~$900-1,000/month. Diabetes coverage generally better than weight-loss coverage. NovoCare self-pay options available for eligible patients. Real out-of-pocket depends on insurance formulary tier, manufacturer savings programs, and whether a direct-pay channel is available.
Can I switch from Foundayo to Rybelsus?+
Switching between brand-name treatments in the same drug class is common, but the conversion is not always 1:1. Discuss the switch with your prescriber — they'll usually re-titrate dosing rather than substitute equivalent strengths directly.
Are Foundayo and Rybelsus the same drug?+
No. Foundayo (orforglipron) and Rybelsus (semaglutide (oral)) are distinct medications from Eli Lilly and Novo Nordisk respectively. They may share a drug class or mechanism but differ in active ingredient, dosing, and approved use.